Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 17/20 | 1.00 |
| ▸ | ESRRG | P62508 | 13/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.91 |
| ▸ | HTR6 | P50406 | 1/20 | 0.91 |
| ▸ | ESRRB | O95718 | 5/20 | 0.77 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.76 |
| ▸ | TP53 | P04637 | 1/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.76 |
| ▸ | MAPT | P10636 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.76 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.76 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.76 |
| ▸ | PLD2 | O14939 | 1/20 | 0.76 |
| ▸ | PGR | P06401 | 1/20 | 0.76 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.76 |
| ▸ | ESRRA | P11474 | 2/20 | 0.74 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 4-Hydroxytormifene SCHEMBL9099337 | 1.00 | ESR1 (1.00) | ESR1ESRRGLMNAHTR6ESRRB | |
| SCHEMBL30421012 | 1.00 | ESR1 (1.00) | ESR1ESRRGLMNAHTR6ESRRB | |
| 4-Hydroxytormifene SCHEMBL906309 | 1.00 | ESR1 (1.00) | ESR1ESRRGLMNAHTR6ESRRB | |
| Toremifene SCHEMBL1152000 | 0.95 | HTR6 (1.00) | ESR1ESRRGLMNAHTR6ESRRB | |
| Toremifene SCHEMBL906278 | 0.95 | HTR6 (1.00) | ESR1ESRRGLMNAHTR6ESRRB | |
| Toremifene SCHEMBL7465 | 0.95 | HTR6 (1.00) | ESR1ESRRGLMNAHTR6ESRRB | |
| SCHEMBL906277 | 0.95 | ESR1 (0.91) | ESR1ESRRGLMNAHTR6ESRRB | |
| SCHEMBL4873146 | 0.95 | ESR1 (0.91) | ESR1ESRRGLMNAHTR6ESRRB | |
| Toremifene SCHEMBL2223880 | 0.94 | HTR6 (0.97) | ESR1ESRRGLMNAHTR6ESRRB | |
| SCHEMBL9099800 | 0.91 | HTR6 (0.86) | ESR1ESRRGLMNAHTR6ESRRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040186185-A1 | Using toremifene and/or analog or metabolite; reducing incidence of premalignant lesions | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2004-09-23 | — | — | US | claimed |
| US-20040092602-A1 | Administering toremifene | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2004-05-13 | — | — | US | claimed |
| US-6413535-B1 | ADMINISTERING CHLORINATED PHENYL COMPOUND | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION | 2002-07-02 | — | — | US | claimed |
| US-5929123-A | LOWERING LEVELS OF SERUM LIPID PEROXIDES, PREVENTION AND TREATMENT OF ATHEROSCLEROSIS, ISCHEMIC INJURY, PSORIASIS, INFLAMMATORY DISEASE, CARDIOVASCULAR DISORDERS AND AIDS | ORION CORPORATION (FI) | 1999-07-27 | — | — | US | claimed |
| EP-0633774-B1 | TOPICAL ADMINISTRATION OF TOREMIFENE AND ITS METABOLITES | ORION YHTYMAE OY (FI) | 1999-02-17 | — | — | EP | claimed |
| US-5491173-A | ESTROGENIC, ANTIESTROGENIC AGENTS, ANTITUMOR AGENTS | ORION-YHTYMA OY (FI) | 1996-02-13 | — | — | US | claimed |
| EP-0633774-A1 | TOPICAL ADMINISTRATION OF TOREMIFENE AND ITS METABOLITES | ORION-YHTYMÄ OY (FI) | 1995-01-18 | — | — | EP | claimed |
| WO-1993019746-A1 | TOPICAL ADMINISTRATION OF TOREMIFENE AND ITS METABOLITES | Orion-Yhtymä Oy (FI) | 1993-10-14 | — | — | WO | claimed |
| JP-3163015-A | — | — | None | — | — | JP | disclosed |
| US-11452731-B2 | Method of treating and preventing loss of cognition | ENDORECHERCHE, INC. | 2022-09-27 | — | — | US | disclosed |
| EP-2277514-A1 | A method for chemoprevention of prostate cancer | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2011-01-26 | — | — | EP | disclosed |
| US-7378445-B2 | Treatment of prostate cancer | PEPLIN RESEARCH PTY. LTD. (AU) | 2008-05-27 | — | — | US | disclosed |
| EP-1771179-A2 | COMPOSITIONS COMPRISING 5-ALPHA REDUCTASE INHIBITORS, AND SERMs AND METHODS OF USE THEREOF | GTX, Inc. (US) | 2007-04-11 | — | — | EP | disclosed |
| US-20060287400-A1 | benign prostatic hyperplasia, prostate intraepithelial neoplasia (PIN), or an abnormally high level of circulating prostate specific antibody (PSA), | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2006-12-21 | — | — | US | disclosed |
| JP-H03163015-A | PREPARATION FOR REVERSAL OF MULTIDRUG RESISTANCE OF CANCER CELL | HARRIS ADRIAN L | 1991-07-15 | — | — | JP | disclosed |
| EP-0415623-A2 | Toremifene or demethyltoremifene as hydroxytoremifene for the reversal of multidrug restistance of cancer cells against cytotoxic drugs | ORION-YHTYMÀ OY (FI) | 1991-03-06 | — | — | EP | disclosed |
| US-4990538-A | Administering for the treatment of cancer | ORION CORPORATION (FI) | 1991-02-05 | — | — | US | disclosed |
| US-4703018-A | PROTEIN BONDING TO SHELL; PARTIAL COVERAGE WITH ANIONIC SURFACTANT; ADDITION POLYMERS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-10-27 | — | — | US | disclosed |
| US-4480042-A | POLYMERS/SHELL-CORE/ | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-10-30 | — | — | US | disclosed |
| US-4401765-A | Covalently bonded high refractive index particle reagents and their use in light scattering immunoassays | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1983-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186185-A1 | Using toremifene and/or analog or metabolite; reducing incidence of premalignant lesions | AR, OPRL1, NR5A1 | ESR1 19/4885ESRRG 181/4885LMNA 547/4885 |
| US-11452731-B2 | Method of treating and preventing loss of cognition | SHBG, BRCA1, CYP19A1 | ESR1 11/4885ESRRG 38/4885LMNA 1986/4885 |
| US-20060287400-A1 | benign prostatic hyperplasia, prostate intraepithelial neoplasia (PIN), or an abnormally high level of circulating prostate specific antibody (PSA), | KLK3, ACP3, BPHL | ESR1 767/4885ESRRG 3107/4885LMNA 297/4885 |
| US-20040092602-A1 | Administering toremifene | OPRL1, OPRK1, NR5A1 | ESR1 26/4885ESRRG 312/4885LMNA 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.